Skip to main content

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.

Publication ,  Conference
Petrylak, DP; Flaig, TW; Mar, N; Gourdin, TS; Srinivas, S; Rosenberg, JE; Guseva, M; Yu, Y; Narayanan, S; Hoimes, CJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Petrylak, D. P., Flaig, T. W., Mar, N., Gourdin, T. S., Srinivas, S., Rosenberg, J. E., … Hoimes, C. J. (2022). Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Petrylak, Daniel P., Thomas W. Flaig, Nataliya Mar, Theodore Stewart Gourdin, Sandy Srinivas, Jonathan E. Rosenberg, Maria Guseva, Yao Yu, Sujata Narayanan, and Christopher J. Hoimes. “Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Petrylak DP, Flaig TW, Mar N, Gourdin TS, Srinivas S, Rosenberg JE, Guseva M, Yu Y, Narayanan S, Hoimes CJ. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible. JOURNAL OF CLINICAL ONCOLOGY. 2022.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences